TABLE 3.
Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With Stage IV Melanoma
| Variable | No. of Patients (%) | P | ||
|---|---|---|---|---|
| Total, N = 53 | Fit Patients, n = 41 | Frail Patients, n = 12 | ||
| Best objective response | .16 | |||
| Complete response | 7 (14.0) | 6 (18.0) | 1 (6.0) | |
| Partial response | 21 (42.0) | 12 (35.0) | 9 (56.0) | |
| Stable disease | 11 (22.0) | 10 (29.0) | 1 (6.0) | |
| Progressive disease | 11 (22.0) | 6 (18.0) | 5 (31.0) | |
| Clinically relevant irAE | 26 (49.0) | 16 (42.0) | 11 (65.0) | .12 |
| Grade ≥3 irAE | 12 (23.0) | 7 (19.0) | 5 (29.0) | .42 |
Abbreviations: G8, Geriatric 8; irAE, immune‐related adverse event.